🎉 M&A multiples are live!
Check it out!

Arvinas Valuation Multiples

Discover revenue and EBITDA valuation multiples for Arvinas and similar public comparables like Vivoryon Therapeutics, Pharming, and Julphar.

Arvinas Overview

About Arvinas

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.


Founded

2013

HQ

United States of America
Employees

430

Website

arvinas.com

Financials

LTM Revenue $242M

LTM EBITDA -$235M

EV

-$521M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Arvinas Financials

Arvinas has a last 12-month revenue of $242M and a last 12-month EBITDA of -$235M.

In the most recent fiscal year, Arvinas achieved revenue of $263M and an EBITDA of -$244M.

Arvinas expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Arvinas valuation multiples based on analyst estimates

Arvinas P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $78.5M $263M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$395M -$244M XXX XXX XXX
EBITDA Margin -503% -92% XXX XXX XXX
Net Profit -$283M -$367M XXX XXX XXX
Net Margin -360% -139% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Arvinas Stock Performance

As of April 15, 2025, Arvinas's stock price is $7.

Arvinas has current market cap of $509M, and EV of -$521M.

See Arvinas trading valuation data

Arvinas Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$521M $509M XXX XXX XXX XXX $-3.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Arvinas Valuation Multiples

As of April 15, 2025, Arvinas has market cap of $509M and EV of -$521M.

Arvinas's trades at -2.2x LTM EV/Revenue multiple, and 2.2x LTM EBITDA.

Analysts estimate Arvinas's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Arvinas and 10K+ public comps

Arvinas Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$521M XXX XXX XXX
EV/Revenue -2.0x XXX XXX XXX
EV/EBITDA 2.1x XXX XXX XXX
P/E -2.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 2.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Arvinas Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Arvinas Valuation Multiples

Arvinas's NTM/LTM revenue growth is -21%

Arvinas's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Arvinas's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Arvinas's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Arvinas and other 10K+ public comps

Arvinas Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 236% XXX XXX XXX XXX
EBITDA Margin -92% XXX XXX XXX XXX
EBITDA Growth -38% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -114% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 63% XXX XXX XXX XXX
R&D Expenses to Revenue 132% XXX XXX XXX XXX
Opex to Revenue 195% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Arvinas Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Arvinas M&A and Investment Activity

Arvinas acquired  XXX companies to date.

Last acquisition by Arvinas was  XXXXXXXX, XXXXX XXXXX XXXXXX . Arvinas acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Arvinas

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Arvinas

When was Arvinas founded? Arvinas was founded in 2013.
Where is Arvinas headquartered? Arvinas is headquartered in United States of America.
How many employees does Arvinas have? As of today, Arvinas has 430 employees.
Who is the CEO of Arvinas? Arvinas's CEO is Dr. John G. Houston, PhD.
Is Arvinas publicy listed? Yes, Arvinas is a public company listed on NAS.
What is the stock symbol of Arvinas? Arvinas trades under ARVN ticker.
When did Arvinas go public? Arvinas went public in 2018.
Who are competitors of Arvinas? Similar companies to Arvinas include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Arvinas? Arvinas's current market cap is $509M
What is the current revenue of Arvinas? Arvinas's last 12-month revenue is $242M.
What is the current EBITDA of Arvinas? Arvinas's last 12-month EBITDA is -$235M.
What is the current EV/Revenue multiple of Arvinas? Current revenue multiple of Arvinas is -2.2x.
What is the current EV/EBITDA multiple of Arvinas? Current EBITDA multiple of Arvinas is 2.2x.
What is the current revenue growth of Arvinas? Arvinas revenue growth between 2023 and 2024 was 236%.
Is Arvinas profitable? Yes, Arvinas is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.